Zimbabwe has rejected a significant US health deal worth $367m (£272m) spanning five years because of the United States' insistence on confidential data.
This rejection was revealed following a internal memorandum from December was disclosed, which showed President Emmerson Mnangagwa felt the deal was "lopsided".
A government spokesman later stated that the United States was seeking genetic material for research and profit but was unwilling to share the resulting advantages from any future treatments.
"We must now begin the challenging and unfortunate task of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had donated more than $1.9bn in health funding to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for further dialogue to find a deal suitable to both sides so the nation's vital HIV programme can continue.
Broader Context
This development comes after a similar case in Kenya, where a high court blocked a related health funding agreement following legal challenges were filed about the safety of citizens' medical information.
Since resuming office recently, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
USAID had managed aid for the US government, but Trump argued its spending was "wasteful" and his administration was seeking direct bilateral agreements to enhance transparency and accountability.
According to reports, 16 African countries have to date signed these new agreements, representing over $18.3bn in new funding.
Specifics of the Rejected Agreement
The funds for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this cooperation could have provided immense benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently on HIV treatment via US-supported initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, without any equivalent guarantee of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might result from that provided information," he stated.
"In essence, our nation would supply the basic resources for scientific discovery with no assurance that the end products would be available to our people should a new health crisis emerge."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were upending structures already set up through the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to deal with future global health emergencies.
"This mechanism is designed to guarantee that when a nation provides its samples, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to develop them."
The government's concerns regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We are open to ongoing discussions with our US partners on how subsequent collaboration might be structured in a way that honours the sovereignty and dignity of each country."
Health Experts Response
Medical experts said it recognised the official position, but urged that talks must proceed given that much of the nation's HIV programmes were funded by foreign aid.
"In cases where technical issues arise, including those relating to information security or implementation frameworks, these can frequently be addressed through technical clarification and negotiated safeguards," the group added.
The halted deal highlights the continuing tensions between receiving much-needed international aid and protecting local interests in an ever more data-driven world.